|Frequency:||Two treatment courses, twelve months apart|
|TGA approval date:||1/09/2010|
|Mechanism of action||As a purine analog, it is a synthetic chemotherapy agent that targets lymphocytes and selectively suppresses the immune system, its exact mechanism of action in MS is not clear.|
|%reduction in relapse rate, impact of progression||57.6% (3.5mg/kg) or 54.5% (5.25mg/kg) reduction.|
|Safe in Pregnancy||Interferes with DNA synthesis and suspected to cause or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage.
Pregnancy should be avoided during treatment and for at least 6 months after the last dose.
Men being treated should take precautions to prevent pregnancy of their partner.
|Breastfeeding (information predominatly from LACTMED database)||It is not known if cladribine is excreted in human milk. Because many meidcations are excreted in human milk and there is no published experience with cladribine during breastfeeding, it should be avoided during breastfeeding.|
|Monitoring requirements||Careful hematologic monitoring is recommended. People are advised to follow the standard cancer screening guidelines.|
|Potential side effects (not a comprehensive list)||Reduction in white blood cells, infections, nausea, diarrhoea, headache, muscle/joint pain, fatigue.|